1-4 of 4
Ursula A. Matulonis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B041: A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation

Elizabeth K. Lee, Andrea E. Wahner Hendrickson, Gerardo Colon-Otero, Cheryl A. Pickett, Niya Xiong, Su-Chun Cheng, Madeline Polak, Hannah Sawyer, Martin Hayes, Ursula A. Matulonis, Geoffrey I. Shapiro, Panagiotis A. Konstantinopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B041.
https://doi.org/10.1158/1535-7163.TARG-23-B041
Published: 01 December 2023
View article titled, Abstract B041: A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation
Journal Articles

FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment

Susumu Shimoyama, Ken Okada, Toshifumi Kimura, Yasushi Morohashi, Shinji Nakayama, Sayaka Kemmochi, Keiko Makita-Suzuki, Ursula A. Matulonis, Mikinaga Mori
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1454–1464.
https://doi.org/10.1158/1535-7163.MCT-23-0099
Published: 01 December 2023
View article titled, FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment
Open the PDF for FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment in another window
Includes: Supplementary data
Journal Articles

Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

Joyce F Liu, Su-Chun Cheng, Robert M Wenham, Andrea E Wahner Hendrickson, Deborah K Armstrong, Nancy Chan, David E Cohn, Jung-Min Lee, Richard T Penson, Mihaela Cristea, James Abbruzzese, Koji Matsuo, Alexander B Olawaiye, Jennifer Curtis, Geoffrey Shapiro, Ursula A Matulonis, Elise Kohn, Percy Ivy, Elizabeth M Swisher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A074.
https://doi.org/10.1158/1535-7163.TARG-19-A074
Published: 01 December 2019
View article titled, Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer
Journal Articles

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (3): 642–655.
https://doi.org/10.1158/1535-7163.MCT-18-0413
Published: 01 March 2019
View article titled, Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Open the PDF for Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness in another window
Includes: Supplementary data